Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39).
about
Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic SuccessesGLP-1 receptor signalling promotes β-cell glucose metabolism via mTOR-dependent HIF-1α activationSelective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetesGlucagon-like peptide-1 (GLP-1) analogs: recent advances, new possibilities, and therapeutic implications.Targeting beta-cell cyclic 3'5' adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review.Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?Structural aspects of gut peptides with therapeutic potential for type 2 diabetes.A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.In vitro and in vivo insulinotropic properties of the multifunctional frog skin peptide hymenochirin-1B: a structure-activity study.Influence of selective fluorination on the biological activity and proteolytic stability of glucagon-like peptide-1.
P2860
Q28067465-3AFA0410-CA73-41B9-89AF-008765FF68A2Q33753096-8331A798-BE87-41B4-BD79-96AF914B723DQ34994502-0910578C-913B-44B2-B132-34D9AA2F2168Q35087846-C352D76E-2D2E-4D48-9253-9C2A1A4942E4Q35962745-06F125A6-C8B9-4F0F-BB1F-FB888B953EE7Q37395298-4A3C5E13-B0A0-453B-8AA8-DA5E47739989Q38071991-2948BB0F-D1CD-4C4E-91F0-AF3118E949B2Q38323074-5C982443-0F15-4E6C-B4F4-8D1411BC1E25Q38830096-C5BD7B0E-720A-480A-A9E6-1D19E276420FQ43177381-D1C6319A-EC8A-481A-921E-46B52472B0FB
P2860
Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39).
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Lys9 for Glu9 substitution in glucagon-like peptide-1
@nl
Lys9 for Glu9 substitution in ...... 9-36)amide and exendin (9-39).
@en
type
label
Lys9 for Glu9 substitution in glucagon-like peptide-1
@nl
Lys9 for Glu9 substitution in ...... 9-36)amide and exendin (9-39).
@en
prefLabel
Lys9 for Glu9 substitution in glucagon-like peptide-1
@nl
Lys9 for Glu9 substitution in ...... 9-36)amide and exendin (9-39).
@en
P2093
P50
P1433
P1476
Lys9 for Glu9 substitution in ...... (9-36)amide and exendin (9-39)
@en
P2093
P304
P356
10.1016/J.METABOL.2003.09.015
P577
2004-02-01T00:00:00Z